Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth

[1]  Y. Niu,et al.  TGF-β1 stimulates epithelial–mesenchymal transition and cancer-associated myoepithelial cell during the progression from in situ to invasive breast cancer , 2019, Cancer cell international.

[2]  Dhiraj Kumar,et al.  Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges , 2018, Molecular Cancer.

[3]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[4]  Thomas E Rohan,et al.  Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism , 2017, Science Translational Medicine.

[5]  O. Klein,et al.  SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling , 2016, Proceedings of the National Academy of Sciences.

[6]  Xin Hu,et al.  Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study , 2016, Scientific Reports.

[7]  P. Chiao,et al.  Amphiregulin in Cancer: New Insights for Translational Medicine. , 2016, Trends in cancer.

[8]  G. Mills,et al.  An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors , 2016, Oncogene.

[9]  P. Kenny,et al.  Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer. , 2015, Cancer research.

[10]  A. Alizadeh,et al.  Tumor suppression effects of myoepithelial cells on mice breast cancer. , 2015, European journal of pharmacology.

[11]  J. Visvader,et al.  Mammary stem cells and the differentiation hierarchy: current status and perspectives , 2014, Genes & development.

[12]  E. Andrechek,et al.  A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer , 2014, Breast Cancer Research.

[13]  L. Qin,et al.  Epidermal Growth Factor Receptor (EGFR) Signaling Promotes Proliferation and Survival in Osteoprogenitors by Increasing Early Growth Response 2 (EGR2) Expression* , 2013, The Journal of Biological Chemistry.

[14]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[15]  S. Hilsenbeck,et al.  Fibroblast Growth Factor Receptor Signaling Is Essential for Normal Mammary Gland Development and Stem Cell Function , 2013, Stem cells.

[16]  Yarong Wang,et al.  Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients , 2012, Breast Cancer Research.

[17]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[18]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[19]  Wenjun Guo,et al.  Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State , 2012, Cell.

[20]  J. Pollard,et al.  Contribution of CXCL12 secretion to invasion of breast cancer cells , 2012, Breast Cancer Research.

[21]  S. Ethier,et al.  Knock‐down of amphiregulin inhibits cellular invasion in inflammatory breast cancer , 2011, Journal of cellular physiology.

[22]  C. Moskaluk,et al.  Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue. , 2011, Genes & development.

[23]  I. Plante,et al.  Evaluation of mammary gland development and function in mouse models. , 2011, Journal of visualized experiments : JoVE.

[24]  G. Kristiansen,et al.  Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis , 2011, Oncogene.

[25]  R. Schiff,et al.  Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study , 2011, Clinical Cancer Research.

[26]  N. Ferrara,et al.  Targeting the tumour vasculature: insights from physiological angiogenesis , 2010, Nature Reviews Cancer.

[27]  B. Paz,et al.  Papillary carcinoma of the breast: an overview , 2010, Breast Cancer Research and Treatment.

[28]  R Snyder,et al.  Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Hans-Peter Lipp,et al.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.

[30]  S. Ethier,et al.  Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. , 2009, Cellular signalling.

[31]  S. Sunnarborg,et al.  The ADAM17–amphiregulin–EGFR Axis in Mammary Development and Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[32]  S. Ethier,et al.  Amphiregulin as a Novel Target for Breast Cancer Therapy , 2008, Journal of Mammary Gland Biology and Neoplasia.

[33]  J. Hanoune.  Amphiregulin is an essential mediator of estrogen receptor a function in mammary gland development. , 2007 .

[34]  S. Abrams,et al.  Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth1 , 2007, The Journal of Immunology.

[35]  Cathrin Brisken,et al.  Amphiregulin is an essential mediator of estrogen receptor α function in mammary gland development , 2007, Proceedings of the National Academy of Sciences.

[36]  S. Ethier,et al.  Autocrine and Juxtacrine Effects of Amphiregulin on the Proliferative, Invasive, and Migratory Properties of Normal and Neoplastic Human Mammary Epithelial Cells* , 2006, Journal of Biological Chemistry.

[37]  R. Gutzmer,et al.  [Cutaneous side effects of EGF-receptor inhibition and their management]. , 2006, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[38]  T. Werfel,et al.  Kutane Nebenwirkungen einer EGF-Rezeptor-Blockade und deren Management , 2006, Der Hautarzt.

[39]  Z. Werb,et al.  Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin , 2005, Development.

[40]  E. J. Lee,et al.  Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. , 2005, Cancer research.

[41]  B. Frenkel,et al.  Gene expression profiling of glucocorticoid-inhibited osteoblasts. , 2004, Journal of molecular endocrinology.

[42]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[43]  J. Thiery,et al.  The importance of being a myoepithelial cell , 2002, Breast Cancer Research.

[44]  B. Fenton,et al.  Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis , 2002, British Journal of Cancer.

[45]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[46]  S. Barsky,et al.  The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype , 2000, Oncogene.

[47]  J. Segall,et al.  A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. , 2000, Cancer research.

[48]  David C. Lee,et al.  Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. , 1999, Development.

[49]  John N. Hutchinson,et al.  Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis , 1998, Molecular and Cellular Biology.

[50]  Z. Shao,et al.  The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  R. Cardiff,et al.  Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.

[52]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[53]  L. Raptis,et al.  Cellular ras gene activity is required for full neoplastic transformation by polyomavirus , 1991, Journal of virology.

[54]  A. Sonnenberg,et al.  The regulation of expression of mouse mammary tumor virus DNA by steroid hormones and growth factors. , 1989, Journal of steroid biochemistry.

[55]  R. Williams,et al.  Altered glucocorticoid binding and action in response to epidermal growth factor in HBL100 cells. , 1987, Cancer research.

[56]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[57]  C. F. Fox,et al.  Epidermal growth factor stimulates tyrosine phosphorylation of human glucocorticoid receptor in cultured cells. , 1987, Biochemical and biophysical research communications.

[58]  K. Yamamoto,et al.  Steroid receptor regulated transcription of specific genes and gene networks. , 1985, Annual review of genetics.

[59]  H. Diggelmann,et al.  Glucocorticoid regulation of mouse mammary tumor virus: identification of a short essential DNA region. , 1983, The EMBO journal.